skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 16.11d (Release date: 2016-11-28)
SearchBox Top
SearchBox Bottom
Ribociclib (Code C95701)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ribociclib

Definition: An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Display Name: Ribociclib

Label: Ribociclib

NCI Thesaurus Code: C95701 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2987342  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
LEE-011
LEE011
Ribociclib
RIBOCICLIB

External Source Codes: 
CAS Registry Number 1211441-98-3 (see NLM ChemIDplus info)
FDA UNII Code TK8ERE8P56
PDQ Closed Trial Search ID 689330
PDQ Open Trial Search ID 689330 (check for NCI PDQ open clinical trial info)
UMLS CUI C2987342

Other Properties:
Name Value (qualifiers indented underneath)
code C95701
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95701

Mainbox Bottom